T 0007/17 (Phyto-Cannabinoids in the treatment of epilepsy/GW PHARMA and OTSUKA PHARMACEUTICAL) of 14.10.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T000717.20211014
- Date of decision
- 14 October 2021
- Case number
- T 0007/17
- Petition for review of
- -
- Application number
- 10734541.5
- IPC class
- A61P 25/08A61K 31/352
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- USE OF ONE OR A COMBINATION OF PHYTO-CANNABINOIDS IN THE TREATMENT OF EPILEPSY
- Applicant name
- GW Pharma Limited
Otsuka Pharmaceutical Co. Limited - Opponent name
- Insys Therapeutics, Inc.
- Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- Decision_President_dated 12 July 2007 on the filing of authorisations_Art_001(1), (2), (3)European Patent Convention Art 99(1)European Patent Convention R 103(4)(a)European Patent Convention R 115(1)European Patent Convention R 115(2)European Patent Convention R 130(1)European Patent Convention R 152(1)European Patent Convention R 152(6)European Patent Convention R 22European Patent Convention R 85Rules of procedure of the Boards of Appeal 2020 Art 015(3)
- Keywords
- Admissibility of appeal
Authorisation
Transfer of opponent status
Postponement of oral proceedings - Catchword
- -
- Cited cases
- G 0004/88G 0008/91G 0003/97G 0004/97G 0003/99G 0002/04G 0001/13J 0019/92T 1204/97T 0247/98T 0009/00T 0956/03T 0006/05T 0425/05T 1421/05T 1911/09T 1700/11T 2136/11T 0796/12T 2357/12
- Citing cases
- -
Order
For these reasons it is decided that:
1. The appellant-opponent's appeal is rejected as
inadmissible.
2. The patent proprietors' appeal fee is to be
reimbursed at 25%.